Pathology of Gastric Intestinal Metaplasia: Clinical Implications

Intestinal metaplasia (IM) of the gastric mucosa is a relatively frequent precancerous lesion (1). The inclusion of IM in a gastric biopsy pathology report often creates uncertainty for the gastroenterologist about the appropriate management. Although the risk of gastric cancer is increased in the presence of IM, the overall risk of gastric cancer in a patient with IM is extremely low compared with the risk of adenocarcinoma in a patient with Barrett’s esophagus (BE)(2). Although the incidence of gastric cancer is high in certain regions, such as Asia and Latin America, it is much lower in the United States and other Western countries, making it difficult to justify broad surveillance programs. The aims of this article are (i) to assist the clinician in identifying subgroups of patients with IM at increased risk for gastric cancer and (ii) to propose an algorithm for gastric IM management, considering the lack of universally accepted guidelines that can be applied to any population.

[1]  K. Ozasa,et al.  Helicobacter pylori Infection and Gastric Cancer (A Nested Case-Control Study in a Rural Area of Japan) , 1997, Digestive Diseases and Sciences.

[2]  N. Yoshimura,et al.  Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer , 2004, International journal of cancer.

[3]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.

[4]  S. Leung,et al.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. , 2004, JAMA.

[5]  R. Peek,et al.  Helicobacter infection and gastric neoplasia , 2006, The Journal of pathology.

[6]  K. Miki,et al.  Using serum pepsinogens wisely in a clinical practice , 2007, Journal of digestive diseases.

[7]  E. Fontham,et al.  Association of Interleukin-1β Gene Polymorphisms with Precancerous Gastric Lesions in African Americans and Caucasians , 2006, The American Journal of Gastroenterology.

[8]  M. Redston,et al.  Morphologic Features are Useful in Distinguishing Barrett Esophagus From Carditis With Intestinal Metaplasia , 2007, The American journal of surgical pathology.

[9]  A. Teixeira,et al.  Mucins as key molecules for the classification of intestinal metaplasia of the stomach , 2002, Virchows Archiv.

[10]  N. Wright,et al.  Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  P. Correa,et al.  Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. , 1992, Cancer research.

[12]  F. Chan,et al.  Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication , 2004, Gut.

[13]  M. Sobrinho-Simões,et al.  Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. , 1999, Cancer research.

[14]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[15]  T. Hirota,et al.  Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. , 1980, Journal of the National Cancer Institute.

[16]  M. Filipe,et al.  Intestinal metaplasia and its variants in the gastric mucosa of Portuguese subjects: a comparative analysis of biopsy and gastrectomy material. , 1986, Human pathology.

[17]  P. Correa,et al.  Sulphomucins favour adhesion of Helicobacter pylori to metaplastic gastric mucosa. , 1999, Journal of clinical pathology.

[18]  D. Faigel,et al.  ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. , 2006, Gastrointestinal endoscopy.

[19]  M. Rugge,et al.  Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.--Interdisciplinary Group on Gastric Epithelial Dysplasia. , 1993, Endoscopy.

[20]  H. Nielsen,et al.  »Small Intestinal Type« and »Colonic Type« Intestinal Metaplasia of The Human Stomach, and Their Relationship to the Histogenetic Types of Gastric Adenocarcinoma , 1978, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[21]  N. Muñoz,et al.  Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia , 1994, International journal of cancer.

[22]  E. Kuipers,et al.  The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. , 2009, Gastrointestinal endoscopy.

[23]  Wai K. Leung,et al.  Intestinal metaplasia and gastric carcinogenesis , 2002 .

[24]  W. Chey,et al.  American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection , 2007, The American Journal of Gastroenterology.

[25]  K. Araki,et al.  Serum Pepsinogen Levels, Helicobacter pylori CagA Status, and Cytokine Gene Polymorphisms Associated with Gastric Premalignant Lesions in Costa Rica , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  N. Muñoz,et al.  Age and Severity of Mucosal Lesions Influence the Performance of Serologic Markers in Helicobacter pylori–Associated Gastroduodenal Pathologies , 2008, Cancer Epidemiology Biomarkers & Prevention.

[27]  M. Fennerty,et al.  Gastric intestinal metaplasia on routine endoscopic biopsy. , 2003, Gastroenterology.

[28]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[29]  P. Correa,et al.  Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. , 1970, Journal of the National Cancer Institute.

[30]  D. McGee,et al.  Gastric intestinal metaplasia in ethnic groups in the southwestern United States. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  M. Gail,et al.  Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. , 2006, Journal of the National Cancer Institute.

[32]  W. You,et al.  Epidemiology of precancerous gastric lesions , 1993, Journal of gastroenterology and hepatology.

[33]  T. Rokkas,et al.  Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. , 1991, Gut.

[34]  E. Fontham,et al.  Long term follow up of patients treated for Helicobacter pylori infection , 2005, Gut.

[35]  Ali Ms Letter: Geriatrics is medicine. , 1974, The Lancet.

[36]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[37]  Charles Wiggins,et al.  Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. , 2007, Cancer.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  F. Di Mario,et al.  Non-invasive tests in gastric diseases. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[41]  A. Lilienfeld,et al.  MODEL FOR GASTRIC CANCER EPIDEMIOLOGY , 1976, The Lancet.

[42]  Xiaocheng Wu,et al.  Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences , 2007, Cancer Causes & Control.

[43]  P. Malfertheiner,et al.  OLGA staging for gastritis: a tutorial. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[44]  Amitabh Srivastava,et al.  Gastric preneoplastic lesions and epithelial dysplasia. , 2007, Gastroenterology clinics of North America.

[45]  K. Miki Gastric cancer screening using the serum pepsinogen test method , 2002, Gastric Cancer.

[46]  K. Heilmann,et al.  Loss of differentiation in intestinal metaplasia in cancerous stomachs. A comparative morphologic study. , 1979, Pathology, research and practice.

[47]  E. Kuipers,et al.  Helicobacter pylori Eradication and Gastric Cancer: When Is the Horse Out of the Barn? , 2009, The American Journal of Gastroenterology.

[48]  J. Sung,et al.  Review article: intestinal metaplasia and gastric carcinogenesis. , 2002, Alimentary pharmacology & therapeutics.

[49]  J. Fraumeni,et al.  Cigarette smoking and other risk factors for progression of precancerous stomach lesions. , 1992, Journal of the National Cancer Institute.

[50]  J. Jass,et al.  The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma , 1981, The Histochemical Journal.

[51]  M. Gail,et al.  Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. , 2000, Journal of the National Cancer Institute.

[52]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[53]  Nayoung Kim,et al.  Progression of Atrophic Gastritis and Intestinal Metaplasia Drives Helicobacter pylori Out of the Gastric Mucosa , 2006, Digestive Diseases and Sciences.

[54]  F. Mégraud,et al.  Helicobacter pylori infection and gastric cancer. , 2006, European journal of cancer.

[55]  M. Cattaruzza,et al.  Long‐term follow‐up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection , 2005, Alimentary pharmacology & therapeutics.

[56]  G. Friedman,et al.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. , 1997, Gut.

[57]  M. Piazuelo,et al.  Phenotypic differences between esophageal and gastric intestinal metaplasia , 2004, Modern Pathology.

[58]  Ming-Shiang Wu,et al.  Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. , 2009, Gastroenterology.

[59]  M. Gail,et al.  Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. , 2001, Journal of the National Cancer Institute.

[60]  D. Graham,et al.  Topographic patterns of intestinal metaplasia and gastric cancer , 2000, American Journal of Gastroenterology.

[61]  L. Brown,et al.  Epidemiologic trends in esophageal and gastric cancer in the United States. , 2002, Surgical oncology clinics of North America.

[62]  J. Goldblum,et al.  Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa , 2002, American Journal of Gastroenterology.

[63]  J. Rotter,et al.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. , 1982, Gastroenterology.

[64]  J. Watari,et al.  Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  S. Vollset,et al.  Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status , 2007, Gut.

[66]  E. Fontham,et al.  Diet and chronic atrophic gastritis: a case-control study. , 1986, Journal of the National Cancer Institute.

[67]  D. Karamanolis,et al.  Premalignant lesions and conditions for gastric adenocarcinoma: diagnosis, management and surveillance guidelines. , 2003, Hepato-gastroenterology.